The team hopes the technology will improve the success rate of cell therapies for patients who have sustained organ damage from chemotherapy, cardiovascular disease and other medical issues.
Tissue engineering represents one of the fastest growing medical markets in the world and is expected to reach a value of $11.5bn by 2022. Clinicians currently face the challenge of knowing how to monitor and continuously test the performance of their lab-grown cells.
